Today millions of people are finding relief using cannabis treatments. Regarding the principles of the Evidence-Based-Medicine (EBM), cannabis and its derivatives are safe and effective treatment agents for common symptoms: pain, spasticity, vomiting, and nausea.
There are high hopes that the known cannabis anti-tumor activity, its direct effects on immunity and other homeostasis mechanisms, will be successfully used for the causal (curative) treatment of a wide range of diseases in the foreseeable future:
- different types of cancer
- hepatitis C
- multiple sclerosis
- Alzheimer's disease and other neurodegenerative disorders,
- epilepsy and seizure disorders
- post-traumatic stress disorder and other psychiatric disorders
- idiopathic inflammatory gastrointestinal disorders
Pre-clinical and observational research demonstrates promising therapeutic applications. However, there is not enough clinical evidence available that would allow the introduction of cannabis-based medications for causal treatment recently.
True potential of cannabis treatments
Conventional pharmaceutical development includes a process of isolating or synthesizing new compounds, observing the effects in vitro and then in vivo before human studies can be used to discover the safety profile and therapeutic benefit. While in cannabis studies, researchers have already observed the therapeutic effect and safety profile in diverse patient groups receiving cannabis in clinical settings. The progress of cannabis and cannabinoid treatments requires further evidence-based exploration with a modern scientific approach to refine the therapeutic applicability of cannabis-based medicines.
Unleashing the true potential of cannabis and cannabinoid treatments does require a cross discipline approach that captures the current knowledge base across the fields of biomedical research, social science, life sciences, and policy research. This cross-discipline approach identifies and solves barriers to progress, and creates a platform for shared knowledge. The diverse interest in cannabis and cannabinoid research spans across academia, research institutes, private endowments, governments, medical professionals, patient advocacy organizations, health services providers and product manufactures.
For further information, please see: